Table I.
Demographic, anthropometric, clinical, and habitual characteristics of Mexican patients with DMT2.
| Pharmacological treatment (oral hypoglycemiants) | ||||
|---|---|---|---|---|
| Characteristics | Glibenclamide (n=11, 5.53%) | Metformin (n=76, 38.19%) | Glibenclamide + Metformin (n=112, 56.28%) | P-value |
| Age (years) | 65.00±5.50 | 61.03±10.99 | 59.99±11.24 | 0.33 |
| Weight (kg) | 64.50a | 71.80a | 67.50a | 0.53 |
| [61.50-67.50] | [60.51-73.60] | [59.00-75.30] | ||
| Sex, n (%) | ||||
| Female | 7 (63.60%) | 57 (75.00%) | 71 (65.10%) | 0.54 |
| Male | 4 (36.40%) | 19 (25.00%) | 38 (34.90%) | 0.67 |
| DMT2 duration (years) | 6.50 [2.00-11.00] | 5.00a [1.00-9.00] | 8.00a [2.00-13.00] | 0.22 |
| Body mass index | 28.27a [24.88-31.11] | 29.39a [22.36-33.20] | 27.58a [24.97-32.59] | 0.14 |
| Overweight (31) | 4 (40.00%) | 36 (47.40%) | 35 (31.50%) | 0.54 |
| Obesity type | ||||
| I | 4 (100.00%) | 21 (58.30%) | 26 (74.30%) | |
| II | 0 | 8 (22.20%) | 6 (17.10%) | |
| III | 0 | 7 (19.40%) | 3 (8.60%) | |
| Tobacco | 0 (0 %) | 10 (26.30%) | 22 (33.80%) | 0.63 |
| Alcohol | 0 (0 %) | 11 (31.40%) | 24 (38.10%) | 0.81 |
| Menopause | 4 (36.40%) | 17 (22.40%) | 11 (10.10%) | 0.74 |
| Place of origin | Mexico City,Puebla,Veracruz | Mexico City, Chiapas,State of Mexico, Hidalgo,Michoacan, Oaxaca,Queretaro, Tlaxcala | Mexico City,State of Mexico, Guerrero,Hidalgo, Oaxaca,Puebla, Tlaxcala | |
Data are expressed as mean ± standard deviation; a = median; [-] = IQR (interquartile range); n (%); P<0.05. DMT2, diabetes mellitus type 2.